Ventilator Associated Pneumonia (VAP) – Pipeline Review, H1 2018

Global Markets Direct’s, ‘Ventilator Associated Pneumonia (VAP) – Pipeline Review, H1 2018’, provides an overview of the Ventilator Associated Pneumonia (VAP) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Ventilator Associated Pneumonia (VAP), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ventilator Associated Pneumonia (VAP) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Ventilator Associated Pneumonia (VAP)

– The report reviews pipeline therapeutics for Ventilator Associated Pneumonia (VAP) by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Ventilator Associated Pneumonia (VAP) therapeutics and enlists all their major and minor projects

– The report assesses Ventilator Associated Pneumonia (VAP) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Ventilator Associated Pneumonia (VAP)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Ventilator Associated Pneumonia (VAP)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Ventilator Associated Pneumonia (VAP) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Adenium Biotech ApS

Aridis Pharmaceuticals LLC

AstraZeneca Plc

Cardeas Pharma Corp

CytaCoat AB

Destiny Pharma Ltd

Dong-A Socio Holdings Co Ltd

Lakewood-Amedex Inc

MedImmune LLC

Meiji Seika Pharma Co Ltd

Melinta Therapeutics Inc

Merck & Co Inc

Motif Bio Plc

Nabriva Therapeutics plc

Polyphor Ltd

Shionogi & Co Ltd

Tetraphase Pharmaceuticals Inc

Theravance Biopharma Inc

Wockhardt Ltd

Zavante Therapeutics Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Ventilator Associated Pneumonia (VAP) Overview 6

Ventilator Associated Pneumonia (VAP) Therapeutics Development 7

Pipeline Overview 7

Pipeline by Companies 8

Products under Development by Companies 11

Ventilator Associated Pneumonia (VAP) Therapeutics Assessment 13

Assessment by Target 13

Assessment by Mechanism of Action 15

Assessment by Route of Administration 17

Assessment by Molecule Type 19

Ventilator Associated Pneumonia (VAP) Companies Involved in Therapeutics Development 21

Adenium Biotech ApS 21

Aridis Pharmaceuticals LLC 21

AstraZeneca Plc 21

Cardeas Pharma Corp 22

CytaCoat AB 22

Destiny Pharma Ltd 23

Dong-A Socio Holdings Co Ltd 23

Lakewood-Amedex Inc 24

MedImmune LLC 24

Meiji Seika Pharma Co Ltd 24

Melinta Therapeutics Inc 25

Merck & Co Inc 25

Motif Bio Plc 26

Nabriva Therapeutics plc 26

Polyphor Ltd 27

Shionogi & Co Ltd 27

Tetraphase Pharmaceuticals Inc 27

Theravance Biopharma Inc 28

Wockhardt Ltd 28

Zavante Therapeutics Inc 29

Ventilator Associated Pneumonia (VAP) Drug Profiles 30

(avibactam + ceftazidime) Drug Profile 30

(cefepime + zidebactam) Drug Profile 35

(ceftolozane sulfate + tazobactam sodium) Drug Profile 36

(cilastatin sodium + imipenem + relebactam) Drug Profile 42

(meropenem + vaborbactam) Drug Profile 44

AA-139 Drug Profile 51

Aerucin Drug Profile 52

amikacin sulfate + fosfomycin Drug Profile 54

AR-401 Drug Profile 56

arbekacin Drug Profile 57

ASN-100 Drug Profile 58

cefiderocol sulfate tosylate Drug Profile 61

EBX-004 Drug Profile 66

eravacycline Drug Profile 67

exeporfinium chloride Drug Profile 76

fosfomycin tromethamine Drug Profile 78

iclaprim Drug Profile 82

lefamulin acetate Drug Profile 89

Mul-1867 Drug Profile 95

murepavadin Drug Profile 97

Nu-2 Drug Profile 100

Nu-3 Drug Profile 101

Panaecin Drug Profile 103

panobacumab Drug Profile 104

POL-7001 Drug Profile 106

Qn-2251 Drug Profile 107

Small Molecules for Bacterial Infections, Ventilator Associated Pneumonia, Sepsis and Surgical Wound Infections Drug Profile 108

sodium hypochlorite Drug Profile 109

suvratoxumab Drug Profile 110

tedizolid phosphate Drug Profile 111

telavancin hydrochloride Drug Profile 119

tosatoxumab Drug Profile 125

Ventilator Associated Pneumonia (VAP) Dormant Projects 127

Ventilator Associated Pneumonia (VAP) Discontinued Products 128

Ventilator Associated Pneumonia (VAP) Product Development Milestones 129

Featured News & Press Releases 129

Appendix 139

Methodology 139

Coverage 139

Secondary Research 139

Primary Research 139

Expert Panel Validation 139

Contact Us 139

Disclaimer 140

List of Tables

List of Tables

Number of Products under Development for Ventilator Associated Pneumonia (VAP), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Ventilator Associated Pneumonia (VAP) Pipeline by Adenium Biotech ApS, H1 2018

Ventilator Associated Pneumonia (VAP) Pipeline by Aridis Pharmaceuticals LLC, H1 2018

Ventilator Associated Pneumonia (VAP) Pipeline by AstraZeneca Plc, H1 2018

Ventilator Associated Pneumonia (VAP) Pipeline by Cardeas Pharma Corp, H1 2018

Ventilator Associated Pneumonia (VAP) Pipeline by CytaCoat AB, H1 2018

Ventilator Associated Pneumonia (VAP) Pipeline by Destiny Pharma Ltd, H1 2018

Ventilator Associated Pneumonia (VAP) Pipeline by Dong-A Socio Holdings Co Ltd, H1 2018

Ventilator Associated Pneumonia (VAP) Pipeline by Lakewood-Amedex Inc, H1 2018

Ventilator Associated Pneumonia (VAP) Pipeline by MedImmune LLC, H1 2018

Ventilator Associated Pneumonia (VAP) Pipeline by Meiji Seika Pharma Co Ltd, H1 2018

Ventilator Associated Pneumonia (VAP) Pipeline by Melinta Therapeutics Inc, H1 2018

Ventilator Associated Pneumonia (VAP) Pipeline by Merck & Co Inc, H1 2018

Ventilator Associated Pneumonia (VAP) Pipeline by Motif Bio Plc, H1 2018

Ventilator Associated Pneumonia (VAP) Pipeline by Nabriva Therapeutics plc, H1 2018

Ventilator Associated Pneumonia (VAP) Pipeline by Polyphor Ltd, H1 2018

Ventilator Associated Pneumonia (VAP) Pipeline by Shionogi & Co Ltd, H1 2018

Ventilator Associated Pneumonia (VAP) Pipeline by Tetraphase Pharmaceuticals Inc, H1 2018

Ventilator Associated Pneumonia (VAP) Pipeline by Theravance Biopharma Inc, H1 2018

Ventilator Associated Pneumonia (VAP) Pipeline by Wockhardt Ltd, H1 2018

Ventilator Associated Pneumonia (VAP) Pipeline by Zavante Therapeutics Inc, H1 2018

Ventilator Associated Pneumonia (VAP) Dormant Projects, H1 2018

Ventilator Associated Pneumonia (VAP) Discontinued Products, H1 2018

List of Figures

List of Figures

Number of Products under Development for Ventilator Associated Pneumonia (VAP), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports